Key Points Question At birth, are the risks of sensitization to cow’s milk formula and food allergy decreased by avoiding or by supplementing with cow’s milk formula? Findings In this randomized clinical trial involving 312 newborns, risks of sensitization to cow’s...
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...
— Late-breaker abstract, “A North American Randomized Controlled Trial (RCT) of Terlipressin plus Albumin for the Treatment of Hepatorenal Syndrome Type 1 (HRS-1)” — STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/...
TORONTO, ON / ACCESSWIRE / October 21, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2b clinical trial evaluating the company’s lead product candidate,...
Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy...
Trial to support anticipated BLA submission in 1H 2022 Lausanne, Switzerland, October 17, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs)...
Email
Text